J&J beats quarterly sales and profit estimates on cancer drug sales
Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter revenues and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
Johnson & Johnson (JNJ) stock fell on Wednesday even as the healthcare giant posted better-than-expected financials for Q4 ...
Minnesota Vikings players J.J. McCarthy, left, and Andrew Van Ginkel attend the Minnesota Timberwolves-Denver Nuggets game on Saturday, Jan. 25, 2025, at Target Center in Minneapolis. / Minnesota ...
Hosted on MSN1d
Vikings QB J.J. McCarthy ‘Looks Great’ Back On The FieldVikings QB J.J. McCarthy missed his rookie season after suffering a knee injury in Minnesota’s preseason opener. When talking ...
Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...
The phone is practically already ringing. The ghosts have been dispensed, Sam Darnold is slinging it, and the Vikings are playoff-bound — with a chance to secure a first round bye in Detroit on ...
(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...
The Vikings are focused on winning a critical Week 18 game agains the Detroit Lions on Sunday that would secure them the No. 1 seed in the NFC heading into the playoffs. Meanwhile, off the field ...
Shares of Johnson & Johnson fell over 2% on Wednesday, hitting nearly one-week lows, despite reporting better-than-expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback